Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Diabetes genomics research has illuminated single nucleotide polymorphism (SNP) in several genes including, fat mass and obesity associated (FTO) (rs9939609 and rs9926289), potassium voltage-gated channel subfamily J member 11 (rs5219), SLC30A 8 (rs13266634) and peroxisome proliferator-activated receptor gamma 2 (rs1805192).
|
31823921 |
2019 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Proliferator-activated receptor gamma Pro12Ala interacts with the insulin receptor substrate 1 Gly972Arg and increase the risk of insulin resistance and diabetes in the mixed ancestry population from South Africa.
|
24447396 |
2014 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The interaction of the PPARγ Pro12Ala polymorphism with diabetes and cardiovascular risk is controversial.
|
22017455 |
2012 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes.
|
21877956 |
2012 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Another PPARγ polymorphism, the C1431T, is in strong linkage disequilibrium with Pro12Ala and has been shown to be associated with body weight, but its association with diabetes is controversial.
|
21795447 |
2011 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our findings shows the association of these two polymorphisms with serum triglyceride levels, which was increased in the order of P12P-CC < P12P-CT < P12A-CC < P12A-CT in the CHD patients with diabetes.
|
21833536 |
2011 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The authors highlight these challenges and biases using an illustrative example: meta-analysis of interactions between the Pro12Ala variant of the peroxisome proliferator-activated receptor gamma (PPARgamma) gene and various diet and lifestyle factors in the risk of diabetes.
|
20406760 |
2010 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Pro12Ala variant in the peroxisome proliferator-activated receptor gamma (PPARG) gene has been associated with diabetes and several cancers.
|
19436234 |
2009 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Studies on the association of the Pro12Ala and C1431T polymorphisms of PPAR? with diabetes and obesity have revealed extensive population-dependent variations.
|
19805902 |
2009 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects.
|
17941898 |
2008 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The data did suggest that risk of cognitive decline is greater when Pro12A</span>la carriers contract diabetes.
|
18280041 |
2008 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer.
|
17763950 |
2008 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The P12A variant of isoform gamma is estimated to reduce diabetes risk by 19% in many populations, and has a large attributable risk because of high prevalence of the normal allele.
|
18388689 |
2008 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has been associated with decreased risk of diabetes and obesity, both disorders linked to cognitive impairment.
|
17052804 |
2008 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma in diabetes risk.
|
17563457 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
We tested the effect-modifying role of Pro12Ala on the 1 year change in obesity-related traits in a randomised clinical trial of treatment with metformin (n = 989), troglitazone (n = 363) or lifestyle modification (n = 1,004) vs placebo (n = 1,000) for diabetes prevention in high-risk individuals.
|
17898990 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Adiponectin values did not differ among these two genotypes even when categorized based on their diabetes status (normal glucose tolerance Pro12Pro 7.9 vs. Pro12Ala 7.7 microg/ml, P = 0.994; diabetes Pro12Pro 4.7 vs. Pro12Ala 5.4 microg/ml, P = 0.622).
|
17335469 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The proline allele at PPARG P12A increases risk for diabetes in persons with impaired glucose tolerance, an effect modified by body mass index.
|
17213274 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
PPARG P12A (rs1801282) was not significantly associated with diabetes or related traits.
|
17903298 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genetic influence of PPARG P12A genotype is modest and is overshadowed by duration of diabetes and systolic blood pressure as the major risk factors for diabetic nephropathy in the Oji-Cree population.
|
17493550 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
There appears to be certain genes which predispose Indians to diabetes while other genes (for example Pro 12 Ala polymorphism of PPAR gamma gene) which afford protection against diabetes and insulin resistance to Caucasians, do not appear to protect Indians.
|
17496355 |
2007 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
A common polymorphism at codon 12 of this gene (Pro12Ala) has been shown to confer protection against diabetes and colorectal cancer.
|
16393309 |
2006 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Across all studies, the Pro12Ala polymorphism had no significant effect on diabetes-related traits.
|
17065690 |
2006 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cumulative rather than synergistic effects of PPARG Pro12Ala and APM1 SNPs on diabetes risk are suggested.
|
16567542 |
2006 |
Diabetes
|
|
0.100 |
GeneticVariation
|
BEFREE |
There were significant associations of the Pro12Ala single nucleotide polymorphism (SNP) genotypes with diabetes in both case-control comparisons (P=0.025 and P=0.039).
|
16401314 |
2005 |